BioDelivery Sciences International Inc Announces Submission Of NDA for BUNAVAIL


Thursday, 1 Aug 2013 07:00am EDT 

BioDelivery Sciences International Inc announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for BUNAVAIL (buprenorphine naloxone buccal film) for the maintenance treatment of opioid dependence. Under the 505(b)(2) regulatory statute, BUNAVAIL will be subject to a ten month review. BUNAVAIL uses BDSI's patented BioErodible MucoAdhesive (BEMA) drug delivery technology to deliver buprenorphine across the buccal mucosa (inside lining of the cheek). BUNAVAIL is formulated with the abuse deterrent agent naloxone and is designed to efficiently and conveniently deliver buprenorphine while potentially overcoming some of the challenges with other dosage forms. 

Company Quote

11.97
-0.68 -5.38%
26 Dec 2014